CT-388 vs Tirzepatide: Signaling-Biased Dual Agonist vs Market Leader

Introduction#

CT-388 and tirzepatide represent two approaches to dual GLP-1/GIP receptor agonism for obesity treatment. Tirzepatide (Mounjaro/Zepbound) by Eli Lilly is the established market leader, with the largest weight reductions of any approved anti-obesity drug and proven superiority over semaglutide. CT-388, developed by Carmot Therapeutics (acquired by Roche for $2.7 billion in 2023), introduces a novel concept: signaling-biased dual agonism designed to minimize receptor desensitization.

What makes CT-388 unique among dual agonists is its deliberate bias toward G-protein signaling while minimizing beta-arrestin recruitment. This pharmacological distinction has a practical implication: reduced receptor internalization may allow CT-388 to maintain its metabolic effects more consistently over time. The phase 2 results -- 22.5% weight loss at 48 weeks with no plateau -- provide early evidence that this approach may translate into meaningful clinical advantages.

Mechanism of Action Comparison#

CT-388#

CT-388 is a once-weekly subcutaneous dual GLP-1/GIP receptor agonist with a critical differentiating feature: signaling bias. CT-388 was designed to produce potent activation of both GLP-1 and GIP receptors while minimizing beta-arrestin recruitment on either receptor.

The significance of this design lies in receptor biology. Most GPCR agonists trigger two downstream pathways: G-protein signaling (which mediates the therapeutic metabolic effects) and beta-arrestin recruitment (which causes receptor internalization and desensitization). By biasing toward G-protein signaling, CT-388 reduces the rate of receptor downregulation, potentially sustaining pharmacological activity between doses.

Preclinical data showed that biased agonism at both GLP-1 and GIP receptors produced greater weight loss and better glycemic control than unbiased agonism in animal models.

Tirzepatide#

Tirzepatide is a 39-amino-acid synthetic peptide with conventional (non-biased) dual agonism at GIPR and GLP-1R. Its potency profile is imbalanced: approximately 5-fold greater potency at GIPR relative to native GIP and about 0.2-fold the potency of native GLP-1 at GLP-1R. A C20 fatty diacid at lysine-20 enables albumin binding and a half-life of approximately 5 days.

The dual activation produces synergistic effects on insulin secretion, glucagon suppression, gastric emptying delay, appetite reduction, and potentially lipid metabolism. Tirzepatide proved that dual incretin agonism produces superior outcomes to GLP-1 agonism alone in the SURPASS-2 head-to-head trial against semaglutide.

Mechanistic Comparison#

Dosing Comparison#

CT-388 Dosing#

CT-388 is administered as a once-weekly subcutaneous injection. Phase 2 studied doses up to 24 mg over 48 weeks. The dose escalation scheme and final phase 3 dosing have not been publicly confirmed. Roche plans to advance CT-388 into phase 3 trials.

Tirzepatide Dosing#

Tirzepatide uses a well-established escalation:

• Starting dose: 2.5 mg weekly for 4 weeks
• Escalation: 2.5 mg increments at minimum 4-week intervals
• Dose range: 2.5, 5, 7.5, 10, 12.5, 15 mg
• Maximum: 15 mg weekly

Supplied as single-dose pre-filled pens with hidden needle design.

Side Effects Comparison#

CT-388 Side Effects#

CT-388's safety profile is based on limited clinical data. GI adverse events were the most common class, consistent with the incretin mechanism, and were predominantly mild to moderate. The treatment discontinuation rate due to adverse events was low at 5.9% in CT-388 arms vs 1.3% in placebo. The signaling-biased mechanism may theoretically improve GI tolerability by reducing receptor desensitization, though this remains unproven in large trials.

Tirzepatide Side Effects#

Tirzepatide's side effect profile is well characterized through over 14,000 patients in SURPASS and SURMOUNT programs. Nausea 12-33%, diarrhea 12-21%, vomiting 5-13%. GI tolerability was comparable to or slightly better than semaglutide in the head-to-head SURPASS-2 trial despite producing greater metabolic effects. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data.

Safety Comparison Table#

Research Evidence Comparison#

CT-388 Research#

CT-388 has early but notable clinical data:

• Phase 1b: Multi-arm, multi-cohort trial in adults with overweight/obesity and adults with obesity and T2D. Mean placebo-adjusted weight loss of 18.8%. 100% of participants achieved >5% loss, 85% >10%, 70% >15%, 45% >20%.
• Phase 2: At 48 weeks, the 24 mg dose produced 22.5% placebo-adjusted weight loss. 95.7% achieved at least 5%, 87% at least 10%, 47.8% at least 20%, 26.1% at least 30%. Weight had not plateaued.
• Phase 3: Planned by Roche

Evidence level: Low-moderate -- promising phase 1b/2 data with impressive responder rates, but small sample sizes and no head-to-head comparisons.

Tirzepatide Research#

• SURPASS (T2D): Five trials, >9,000 patients. SURPASS-2 showed superiority over semaglutide 1 mg: HbA1c -2.46% vs -1.86%, weight -12.4 kg vs -6.2 kg at 40 weeks
• SURMOUNT (obesity): SURMOUNT-1 demonstrated 20.9% mean weight loss at 72 weeks (15 mg). 36% achieved 25% or more
• SURPASS-CVOT: Cardiovascular outcomes trial underway

Evidence level: High -- large RCTs, head-to-head data, FDA-approved for two indications.

Key Differences Summary#

• Signaling bias: CT-388's primary innovation. By minimizing beta-arrestin recruitment, CT-388 may sustain receptor activation and reduce desensitization. Tirzepatide uses conventional agonism.
• Weight loss: CT-388 showed 22.5% at 48 weeks (phase 2). Tirzepatide showed 20.9% at 72 weeks (phase 3, SURMOUNT-1). Direct comparison is limited by different study designs, durations, and patient populations.
• Responder rates: CT-388 had 26.1% of participants losing 30% or more body weight. Tirzepatide had 36% losing 25% or more.
• Evidence maturity: Tirzepatide has extensive phase 3 data and FDA approval. CT-388 has phase 2 data and plans for phase 3.
• Regulatory status: Tirzepatide is commercially available. CT-388 is years from potential approval.
• Combination potential: Roche has a separate oral GLP-1 program (CT-996) that could complement CT-388, similar to how Eli Lilly pairs tirzepatide with other pipeline assets.

Conclusion#

This comparison highlights how rapidly the dual agonist space is evolving. Tirzepatide established the paradigm -- proving that dual GLP-1/GIP agonism produces superior outcomes to GLP-1 agonism alone -- and remains the clear choice for patients today. Its extensive evidence base, FDA approval, and commercial availability are unmatched.

CT-388 represents a pharmacologically sophisticated refinement of the dual agonist concept. Its signaling-biased design addresses a fundamental limitation of conventional GPCR agonists: receptor desensitization over time. The phase 2 results are encouraging, with 22.5% weight loss at 48 weeks and no plateau suggesting that the biased mechanism may translate into sustained clinical benefit. The responder rate showing 26.1% of patients achieving 30% or more weight loss is particularly notable.

The key question is whether CT-388's signaling bias provides a clinically meaningful advantage over tirzepatide's conventional agonism in properly powered phase 3 trials. If confirmed, CT-388 could challenge tirzepatide's position as the most effective injectable dual agonist. Until then, tirzepatide remains the evidence-based standard of care.

Further Reading#

• CT-388 Overview and Research Guide
• CT-388 Side Effects
• CT-388 Dosing Protocols
• Tirzepatide Overview and Research Guide
• Tirzepatide Side Effects
• Tirzepatide Dosing Protocols